文献速递肿瘤 PET/CT甲状腺核医学

Al18F-NOTA-HER2-BCH PET对HER2阳性乳腺癌患者淋巴结转移的可检测性

Detectability of Al 18 F-NOTA-HER2-BCH PET for Nodal Metastases in Patients With HER2-Positive Breast Cancer.
PubMed 文献 · Clin Nucl Med · 2025-01-24

这项回顾性研究纳入62例病理证实的HER2阳性乳腺癌患者,均行Al18F-NOTA-HER2-BCH与18F-FDG PET/CT。Al18F-NOTA-HER2-BCH在患者水平敏感度和特异度分别为0.97和0.97,18F-FDG为0.85和0.77;病灶水平Al18F-NOTA-HER2-BCH检出了更多腋窝、腋外及非区域淋巴结转移,尤其是小于10 mm的病灶。

要点

  • 患者水平Al18F-NOTA-HER2-BCH敏感度0.97、特异度0.97,18F-FDG为0.85、0.77。
  • Al18F-NOTA-HER2-BCH检出更多腋窝(98.8% vs 70.2%)、腋外(100% vs 61.7%)及非区域(99.1% vs 67.0%)淋巴结转移。
  • 小于10 mm淋巴结转移Al18F-NOTA-HER2-BCH检出198个(99.5%),18F-FDG检出125个(62.8%)。

核心结论

  • Al18F-NOTA-HER2-BCH PET/CT在HER2阳性乳腺癌患者中检出的区域和非区域淋巴结转移多于18F-FDG PET/CT,尤其对小于10 mm的病灶。

研究设计与样本

  • 回顾性研究,纳入62例病理证实的HER2阳性乳腺癌患者(IHC 3+或IHC 2+且FISH基因扩增),均行Al18F-NOTA-HER2-BCH和18F-FDG PET/CT,由三名独立读者视觉评估示踪剂摄取,并用c统计量评估淋巴结转移诊断准确性。

主要发现

  • 33例(53%)患者发现淋巴结转移,其中45%仅有区域淋巴结转移,55%有非区域淋巴结转移。
  • 患者水平基于多数读者判读,Al18F-NOTA-HER2-BCH的敏感度和特异度分别为0.97和0.97,18F-FDG分别为0.85和0.77。
  • 5例患者仅Al18F-NOTA-HER2-BCH显像可见;7例仅18F-FDG PET/CT高摄取者经病理和后续影像随访证实为炎性摄取。
  • 病灶水平Al18F-NOTA-HER2-BCH PET/CT较18F-FDG PET/CT检出更多腋窝(98.8% vs 70.2%)、腋外(100% vs 61.7%)和非区域(99.1% vs 67.0%)淋巴结转移,以及更多小于10 mm的淋巴结转移(198个 vs 125个,99.5% vs 62.8%)。
  • 区域或非区域淋巴结转移在Al18F-NOTA-HER2-BCH的中位SUVmax和TBR均高于18F-FDG(中位SUVmax范围8.0-11.4 vs 2.3-5.6,P范围<0.001-0.007;中位TBR范围7.3-16.3 vs 2.9-5.3,P范围<0.001)。

关键数值与推荐

  • 患者水平Al18F-NOTA-HER2-BCH敏感度0.97、特异度0.97,18F-FDG敏感度0.85、特异度0.77。
  • 病灶水平腋窝淋巴结转移检出率Al18F-NOTA-HER2-BCH 98.8% vs 18F-FDG 70.2%,腋外100% vs 61.7%,非区域99.1% vs 67.0%。
  • 小于10 mm淋巴结转移检出数Al18F-NOTA-HER2-BCH 198个(99.5%) vs 18F-FDG 125个(62.8%)。
  • 区域或非区域淋巴结转移中位SUVmax Al18F-NOTA-HER2-BCH 8.0-11.4 vs 18F-FDG 2.3-5.6(P范围<0.001-0.007)。
  • 区域或非区域淋巴结转移中位TBR Al18F-NOTA-HER2-BCH 7.3-16.3 vs 18F-FDG 2.9-5.3(P范围<0.001)。

临床怎么用

  • 所有62例参与者中未观察到与显像剂相关的不良反应。
  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to compare Al 18 F-NOTA-HER2-BCH and 18 F-FDG for detecting nodal metastases in patients with HER2-positive breast cancer on PET/CT. PATIENTS AND METHODS: In this retrospective study, 62 participants with HER2-positive breast cancer underwent both Al 18 F-NOTA-HER2-BCH and 18 F-FDG PET/CT. Participants were pathologically confirmed as HER2-positive (IHC 3+ or IHC 2+ with gene amplification on FISH). Three independent readers visually assessed uptake of tracers on imaging. Furthermore, the diagnostic accuracy of nodal metastases was assessed using c-statistics. The lesion uptakes were quantified by SUV max and target-to-background ratio (TBR) and compared using the general linear mixed model. RESULTS: The findings showed nodal metastases in 33 (53%) participants, including 45% only with regional nodal metastasis and 55% with nonregional nodal metastasis. On per-patient level, the sensitivity and specificity of Al 18 F-NOTA-HER2-BCH and 18 F-FDG based on the majority reads were 0.97, 0.97, and 0.85, 0.77, respectively. Five participants were visualized only on Al 18 F-NOTA-HER2-BCH. Seven participants with high uptake only on 18 F-FDG PET/CT were confirmed to be inflammatory uptake by pathological results and later imaging follow-up. On per-lesion level, Al 18 F-NOTA-HER2-BCH PET/CT detected more axillary (98.8% vs 70.2%), extra-axillary (100% vs 61.7%), and nonregional (99.1% vs 67.0%) lymph nodal metastases than 18 F-FDG PET/CT. Additionally, Al 18 F-NOTA-HER2-BCH PET/CT detected more nodal metastases small than 10 mm than 18 F-FDG PET/CT (198 vs 125, 99.5% vs 62.8%). The median SUV max and TBR of regional or nonregional nodal metastases at Al 18 F-NOTA-HER2-BCH were all higher than those on 18 F-FDG (range of median SUV max , 8.0-11.4 vs 2.3-5.6; P range, <0.001-0.007; range of median TBR, 7.3-16.3 vs 2.9-5.3; P range, <0.001). No adverse reactions related to imaging agents were observed in all participants. CONCLUSIONS: Al 18 F-NOTA-HER2-BCH PET/CT detected more regional and nonregional lymph nodal metastases in patients with HER2-positive breast cancer than on 18 F-FDG PET/CT, especially for lesions small than 10 mm.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Guo X, Liu J, Lin S, et al. Detectability of Al 18 F-NOTA-HER2-BCH PET for Nodal Metastases in Patients With HER2-Positive Breast Cancer. Clin Nucl Med. 2025. PMID: 39854676. doi:10.1097/RLU.0000000000005686

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。